Alexandria Real Estate Equities, Inc. reported its second quarter 2026 financial results on Monday, Aug. 3 [1].
The results provide a critical look at the stability of life-science real estate during a period of shifting capital plans and operational adjustments.
The company reported adjusted funds from operations (AFFO) of $1.73 per diluted share [2]. This figure aligns with the quarterly funds from operations (FFO) of $1.73 per share [5]. This result surpassed the Zacks Consensus Estimate of $1.65 per share [6]. However, the FFO is lower than the $2.33 per share reported in the second quarter of 2025 [7].
Financial estimates leading up to the announcement included a consensus earnings per share (EPS) estimate of $0.12 [3] and a consensus revenue estimate of $655 million [3]. The company also said that its net loss for the second quarter narrowed compared with the prior year [8].
Regarding future outlook, the company reaffirmed its full-year 2026 guidance midpoint at $6 [2]. The life-science focused real estate investment trust used the announcement to update investors on its current financial performance and capital plans [1].
As a specialized REIT, the company's performance is closely tied to the research and development spending of biotechnology and pharmaceutical firms. The narrowing net loss suggests a stabilization in costs or revenue streams relative to the previous year's performance [8].
“Adjusted funds from operations (AFFO) for Q2 2026 were $1.73 per diluted share.”
The narrowing net loss and reaffirmed guidance suggest that Alexandria Real Estate Equities is maintaining a steady course despite a year-over-year decline in funds from operations. By beating consensus FFO estimates, the company demonstrates resilience in its specialized life-science portfolio, though the gap between 2025 and 2026 figures indicates the sector may still be adjusting to a new economic baseline.
